keyword
MENU ▼
Read by QxMD icon Read
search

Ebola vaccine

keyword
https://www.readbyqxmd.com/read/28081225/fighting-ebola-a-window-for-vaccine-re-evaluation
#1
Keith J Chappell, Daniel Watterson
No abstract text is available yet for this article.
January 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28075069/ebola-vaccination-using-a-dna-vaccine-coated-on-plga-pll-%C3%AE-pga-nanoparticles-administered-using-a-microneedle-patch
#2
Hung-Wei Yang, Ling Ye, Xin Dong Guo, Chinglai Yang, Richard W Compans, Mark R Prausnitz
Ebola DNA vaccine is incorporated into PLGA-PLL/γPGA nanoparticles and administered to skin using a microneedle (MN) patch. The nanoparticle delivery system increases vaccine thermostability and immunogenicity compared to free vaccine. Vaccination by MN patch produces stronger immune responses than intramuscular administration.
January 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28057259/modified-vaccinia-virus-ankara-history-value-in-basic-research-and-current-perspectives-for-vaccine-development
#3
A Volz, G Sutter
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment...
2017: Advances in Virus Research
https://www.readbyqxmd.com/read/28042619/beating-the-odds-successful-establishment-of-a-phase-ii-iii-clinical-research-trial-in-resource-poor-liberia-during-the-largest-ever-ebola-outbreak
#4
J Doe-Anderson, B Baseler, P Driscoll, M Johnson, J Lysander, L McNay, W S Njoh, M Smolskis, L Wehrlen, J Zuckerman
It has been argued that a country such as Liberia, not fully recovered from the devastation of decades of civil unrest, lacked the appropriate ethical and regulatory framework, basic human and health care services, and infrastructure to carry out clinical trials according to international standards of quality during a public health emergency. However, as Liberia, Sierra Leone, and Guinea were being ravaged by the largest and most devastating Ebola Virus Disease (EVD) outbreak ever recorded, the topic of conducting clinical trials of experimental vaccine and treatment candidates in these resource-poor countries generated the keen interest and concern of scientists, researchers, physicians, bioethicists, philanthropists, and even politicians...
December 15, 2016: Contemporary Clinical Trials Communications
https://www.readbyqxmd.com/read/28040206/interest-in-an-ebola-vaccine-among-a-u-s-national-sample-during-the-height-of-the-2014-2016-ebola-outbreak-in-west-africa
#5
Julia E Painter, Ralph J DiClemente, Michael E von Fricken
To better understand the association between Ebola-related attitudes and interest in receiving an Ebola virus vaccine, a survey was administered to a U.S. national sample using GfK's KnowledgePanel®. Among participants (N=1417), 34.1% expressed interest in an Ebola vaccine for themselves. In the subset of participants with children aged 0-17 (N=410), 38.1% expressed interest in an Ebola vaccine for their child. In multivariable analyses, vaccine interest for oneself was associated with perceived susceptibility to Ebola (p=0...
December 28, 2016: Vaccine
https://www.readbyqxmd.com/read/28025125/production-purification-and-immunogenicity-of-recombinant-ebola-virus-proteins-a-comparison-of-freund-s-adjuvant-and-adjuvant-system-03
#6
Krister Melén, Laura Kakkola, Felix He, Kari Airenne, Olli Vapalahti, Helen Karlberg, Ali Mirazimi, Ilkka Julkunen
There is an urgent need for Ebola virus (EBOV) proteins, EBOV-specific antibodies and recombinant antigens to be used in diagnostics and as potential vaccine candidates. Our objective was to produce and purify recombinant proteins for immunological assays and for the production of polyclonal EBOV specific antibodies. In addition, a limited comparison of the adjuvant effects of Freund's complete adjuvant (FCA) and adjuvant system 03 (AS03) was carried out. Recombinant EBOV GST-VP24, -VP30, -VP35, -VP40 and -NP were produced in E...
December 23, 2016: Journal of Virological Methods
https://www.readbyqxmd.com/read/28024952/real-time-dynamic-modelling-for-the-design-of-a-cluster-randomized-phase-3-ebola-vaccine-trial-in-sierra-leone
#7
A Camacho, R M Eggo, N Goeyvaerts, A Vandebosch, R Mogg, S Funk, A J Kucharski, C H Watson, T Vangeneugden, W J Edmunds
BACKGROUND: Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vaccine trials during the tail of the 2013-16 Ebola virus disease (EVD) epidemic in West Africa. Mathematical models can provide forecasts of expected incidence through time and can account for both vaccine efficacy in participants and effectiveness in populations. Determining expected disease incidence was critical to calculating power and determining trial sample size. METHODS: In real-time, we fitted, forecasted, and simulated a proposed phase 3 cluster-randomized vaccine trial for a prime-boost EVD vaccine in three candidate regions in Sierra Leone...
December 23, 2016: Vaccine
https://www.readbyqxmd.com/read/28017642/immunity-duration-of-a-recombinant-adenovirus-type-5-vector-based-ebola-vaccine-and-a-homologous-prime-boost-immunisation-in-healthy-adults-in-china-final-report-of-a-randomised-double-blind-placebo-controlled-phase-1-trial
#8
Jing-Xin Li, Li-Hua Hou, Fan-Yue Meng, Shi-Po Wu, Yue-Mei Hu, Qi Liang, Kai Chu, Zhe Zhang, Jun-Jie Xu, Rong Tang, Wen-Juan Wang, Pei Liu, Jia-Lei Hu, Li Luo, Rong Jiang, Feng-Cai Zhu, Wei Chen
BACKGROUND: The 2013-15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a homologous vector in healthy adults in China. METHODS: In a randomised, double-blind, placebo-controlled, phase 1 clinical trial in one site in Jiangsu Province, China, 120 healthy adults aged 18-60 years received an initial dose of intramuscular adenovirus type-5 Ebola virus vaccine of 4·0 × 10(10) viral particles, 1·6 × 10(11) viral particles, or placebo, and were followed up to day 168...
December 22, 2016: Lancet Global Health
https://www.readbyqxmd.com/read/28017432/beyond-cost-effectiveness-using-systems-analysis-for-infectious-disease-preparedness
#9
Charles Phelps, Guruprasad Madhavan, Rino Rappuoli, Rita Colwell, Harvey Fineberg
Until the recent outbreaks, Ebola vaccines ranked low in decision makers' priority lists based on cost-effectiveness analysis and (or) corporate profitability. Despite a relatively small number of Ebola-related cases and deaths (compared to other causes), Ebola vaccines suddenly leapt to highest priority among international health agencies and vaccine developers. Clearly, earlier cost-effectiveness analyses badly missed some factors affecting real world decisions. Multi-criteria systems analysis can improve evaluation and prioritization of vaccine development and also of many other health policy and investment decisions...
December 22, 2016: Vaccine
https://www.readbyqxmd.com/read/28017405/safety-and-immunogenicity-of-a-recombinant-adenovirus-vector-based-ebola-vaccine
#10
Martin P Grobusch, Abraham Goorhuis
No abstract text is available yet for this article.
December 22, 2016: Lancet
https://www.readbyqxmd.com/read/28017403/efficacy-and-effectiveness-of-an-rvsv-vectored-vaccine-in-preventing-ebola-virus-disease-final-results-from-the-guinea-ring-vaccination-open-label-cluster-randomised-trial-ebola-%C3%A3-a-suffit
#11
Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, Conall H Watson, W John Edmunds, Matthias Egger, Miles W Carroll, Natalie E Dean, Ibrahima Diatta, Moussa Doumbia, Bertrand Draguez, Sophie Duraffour, Godwin Enwere, Rebecca Grais, Stephan Gunther, Pierre-Stéphane Gsell, Stefanie Hossmann, Sara Viksmoen Watle, Mandy Kader Kondé, Sakoba Kéïta, Souleymane Kone, Eewa Kuisma, Myron M Levine, Sema Mandal, Thomas Mauget, Gunnstein Norheim, Ximena Riveros, Aboubacar Soumah, Sven Trelle, Andrea S Vicari, John-Arne Røttingen, Marie-Paule Kieny
BACKGROUND: rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa. METHODS: We did an open-label, cluster-randomised ring vaccination trial (Ebola ça Suffit!) in the communities of Conakry and eight surrounding prefectures in the Basse-Guinée region of Guinea, and in Tomkolili and Bombali in Sierra Leone...
December 23, 2016: Lancet
https://www.readbyqxmd.com/read/28017402/first-ebola-virus-vaccine-to-protect-human-beings
#12
Thomas W Geisbert
No abstract text is available yet for this article.
December 22, 2016: Lancet
https://www.readbyqxmd.com/read/28017399/safety-and-immunogenicity-of-a-recombinant-adenovirus-type-5-vector-based-ebola-vaccine-in-healthy-adults-in-sierra-leone-a-single-centre-randomised-double-blind-placebo-controlled-phase-2-trial
#13
Feng-Cai Zhu, Alie H Wurie, Li-Hua Hou, Qi Liang, Yu-Hua Li, James B W Russell, Shi-Po Wu, Jing-Xin Li, Yue-Mei Hu, Qiang Guo, Wen-Bo Xu, Abdul R Wurie, Wen-Juan Wang, Zhe Zhang, Wen-Jiao Yin, Manal Ghazzawi, Xu Zhang, Lei Duan, Jun-Zhi Wang, Wei Chen
BACKGROUND: A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in Sierra Leone and to determine the optimal dose. METHODS: We did a single-centre, randomised, double-blind, placebo-controlled, phase 2 clinical trial at Sierra Leone-China Friendship Hospital, Freetown, Sierra Leone...
December 22, 2016: Lancet
https://www.readbyqxmd.com/read/28011879/ebola-vaccine-is-highly-protective-show-latest-study-results
#14
Zosia Kmietowicz
No abstract text is available yet for this article.
December 23, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28004307/the-potential-of-social-media-and-internet-based-data-in-preventing-and-fighting-infectious-diseases-from-internet-to-twitter
#15
Khaled Al-Surimi, Mohammed Khalifa, Salwa Bahkali, Ashraf El-Metwally, Mowafa Househ
Health threats due to infectious diseases used to be a major public health concerns around the globe till mid of twentieth century when effective public health interventions helped in eradicating a number of infectious diseases around the world. Over the past 15 years, there has been a rise in the number of emerging and reemerging infectious diseases being reported such as the Acute Respiratory Syndrome (SARS) in 2002, HINI in 2009, Middle East Respiratory Syndrome (MERS) in 2012, Ebola in 2014, and Zika in 2016...
December 22, 2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27989900/ebola-virus-vaccines-where-do-we-stand
#16
REVIEW
Vincent Pavot
The recent outbreak of Ebola virus disease in West Africa has led to more than 11,000 deaths, with a peak in mortality from August through December of 2014. A meeting convened by the World Health Organization (WHO) in September 2014, concluded that an urgent unmet need exists for efficacy and safety testing of the Ebola virus vaccine candidates and that clinical trials should be expedited. These vaccines could be used both in an outbreak setting and to provide long-term protection in populations at risk of sporadic outbreaks...
October 28, 2016: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/27976688/a-hamster-model-for-marburg-virus-infection-accurately-recapitulates-marburg-hemorrhagic-fever
#17
Andrea Marzi, Logan Banadyga, Elaine Haddock, Tina Thomas, Kui Shen, Eva J Horne, Dana P Scott, Heinz Feldmann, Hideki Ebihara
Marburg virus (MARV), a close relative of Ebola virus, is the causative agent of a severe human disease known as Marburg hemorrhagic fever (MHF). No licensed vaccine or therapeutic exists to treat MHF, and MARV is therefore classified as a Tier 1 select agent and a category A bioterrorism agent. In order to develop countermeasures against this severe disease, animal models that accurately recapitulate human disease are required. Here we describe the development of a novel, uniformly lethal Syrian golden hamster model of MHF using a hamster-adapted MARV variant Angola...
December 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27959626/the-pathogenesis-of-ebola-virus-disease
#18
Laura Baseler, Daniel S Chertow, Karl M Johnson, Heinz Feldmann, David M Morens
For almost 50 years, ebolaviruses and related filoviruses have been repeatedly reemerging across the vast equatorial belt of the African continent to cause epidemics of highly fatal hemorrhagic fever. The 2013-2015 West African epidemic, by far the most geographically extensive, most fatal, and longest lasting epidemic in Ebola's history, presented an enormous international public health challenge, but it also provided insights into Ebola's pathogenesis and natural history, clinical expression, treatment, prevention, and control...
December 7, 2016: Annual Review of Pathology
https://www.readbyqxmd.com/read/27942840/expression-of-an-immunogenic-ltb-based-chimeric-protein-targeting-zaire-ebolavirus-epitopes-from-gp1-in-plant-cells
#19
Regina Ríos-Huerta, Elizabeth Monreal-Escalante, Dania O Govea-Alonso, Carlos Angulo, Sergio Rosales-Mendoza
An antigenic protein targeting two epitopes from the Zaire ebolavirus GP1 protein was expressed in plant cells rendering an antigen capable of inducing humoral responses in mouse when administered subcutaneously or orally. The 2014 Ebola outbreak made clear that new treatments and prophylactic strategies to fight this disease are needed. Since vaccination is an intervention that could achieve the control of this epidemic disease, exploring the production of new low-cost vaccines is a key path to consider; especially in developing countries...
December 9, 2016: Plant Cell Reports
https://www.readbyqxmd.com/read/27930961/novel-activities-by-ebolavirus-and-marburgvirus-interferon-antagonists-revealed-using-a-standardized-in-vitro-reporter-system
#20
Jonathan C Guito, César G Albariño, Ayan K Chakrabarti, Jonathan S Towner
Filoviruses are highly lethal in humans and nonhuman primates, likely due to potent antagonism of host interferon (IFN) responses early in infection. Filoviral protein VP35 is implicated as the major IFN induction antagonist, while Ebola virus (EBOV) VP24 or Marburg virus (MARV) VP40 are known to block downstream IFN signaling. Despite progress elucidating EBOV and MARV antagonist function, those for most other filoviruses, including Reston (RESTV), Sudan (SUDV), Taï Forest (TAFV), Bundibugyo (BDBV) and Ravn (RAVV) viruses, remain largely neglected...
January 15, 2017: Virology
keyword
keyword
41124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"